Study guide
16.2 Health Promotion: Smoking Cessation, Weight Management, Screening & Social Determinants of Health
PEBC Pharmacist Qualifying Examination Part I MCQ
Track your progress as you read
Finished sections get a check mark.
1 Chapter 1: Canadian Pharmacy Regulatory Framework & Federal Legislation
1.1 Food and Drugs Act, Regulations, and Health Canada Oversight 1.2 Controlled Drugs and Substances Act (CDSA) & Controlled Substances Regulations (CSR) 1.3 NAPRA Drug Scheduling Framework & National Model Standards of Practice
2 Chapter 2: Ethics, Scope of Practice & Safety Culture
2.1 Professional Ethics, Fiduciary Duty & Health Information Privacy 2.2 Expanded Scope of Practice: Minor Ailments Prescribing, Renewals & Injections 2.3 Equity, Diversity, Inclusion, Cultural Safety & Continuous Quality Improvement
3 Chapter 3: Pharmaceutical Calculations & Posology
3.1 Concentrations, Dilutions, Alligations & Reconstitution 3.2 Dosing by Weight/BSA, Days Supply & Pediatric/Geriatric Dose Adjustments 3.3 IV Infusion Rates, Drop Factors, Osmolarity & Creatinine Clearance (Cockcroft-Gault)
4 Chapter 4: Compounding, Dispensing & Product Integrity
4.1 Non-Sterile Compounding & Beyond-Use Dating (NAPRA Standards) 4.2 Sterile Preparations & Hazardous Drug Handling (NAPRA / NIOSH Principles) 4.3 Prescription Verification, Auxiliary Labeling, Cold Chain & Medication Incident Prevention (ISMP Canada) 4.4 Dispensing Operations: Interchangeability, Adjudication, Compliance Packaging, Release & Inventory Control
5 Chapter 5: Clinical Pharmacology & Pharmacokinetics
5.1 Pharmacokinetic Principles: Clearance, Volume of Distribution, Half-life & Steady State 5.2 Cytochrome P450 Enzymes, Transporters & Significant Drug-Drug Interactions 5.3 Therapeutic Drug Monitoring (TDM), Narrow Therapeutic Index Drugs & Toxicities
6 Chapter 6: Evidence-Based Medicine & Literature Appraisal
6.1 Study Designs, Bias & Levels of Evidence in Clinical Research 6.2 Biostatistics: ARR, RRR, NNT, NNH, Confidence Intervals & P-values 6.3 Applying Canadian Practice Guidelines to Clinical Decision-Making 6.4 Drug Information Practice, Diagnostic Test Accuracy & Pharmacoeconomics
7 Chapter 7: Cardiovascular Pharmacotherapy: Hypertension, Dyslipidemia & CAD
7.1 Hypertension Management (Hypertension Canada Guidelines, Targets & Regimens) 7.2 Dyslipidemia & Atherosclerotic Cardiovascular Disease (CCS Guidelines & Statin Therapy) 7.3 Ischemic Heart Disease & Acute Coronary Syndromes (Antiplatelet & Antianginal Therapy)
8 Chapter 8: Cardiovascular Pharmacotherapy: Heart Failure, Arrhythmias & Anticoagulation
8.1 Heart Failure with Reduced & Preserved Ejection Fraction (GDMT & Monitoring) 8.2 Atrial Fibrillation, Arrhythmias & Rate vs. Rhythm Control 8.3 Venous Thromboembolism & Anticoagulation Therapy (DOACs, Warfarin & Thrombosis Canada)
9 Chapter 9: Endocrine & Metabolic Disorders
9.1 Type 2 Diabetes: Glycemic Targets, Non-Insulin Pharmacotherapy (Diabetes Canada) 9.2 Insulin Regimens, Type 1 Diabetes, Hypoglycemia & Diabetic Emergencies (DKA/HHS) 9.3 Thyroid Disorders & Osteoporosis (Diagnostic Parameters & Therapeutic Management)
10 Chapter 10: Respiratory & Gastrointestinal Disorders
10.1 Asthma Management & Exacerbations (CTS Guidelines, Relievers & Controllers) 10.2 Chronic Obstructive Pulmonary Disease (COPD) & Inhaler Delivery Systems 10.3 Gastroesophageal Reflux Disease (GERD), Peptic Ulcer Disease & GI Bleeding 10.4 Lower GI & Liver Disorders: Constipation, Diarrhea, IBS, IBD & Cirrhosis
11 Chapter 11: Infectious Diseases & Antimicrobial Stewardship
11.1 Respiratory Tract Infections: Otitis, Sinusitis, Pharyngitis, CAP & HAP 11.2 Urinary Tract, Skin/Soft Tissue & Sexually Transmitted Infections 11.3 Systemic Infections, Clostridioides difficile & Antimicrobial Stewardship Principles 11.4 HIV Prevention & Treatment, Viral Hepatitis, Tuberculosis & Fungal Infections
12 Chapter 12: Central Nervous System & Mental Health
12.1 Major Depressive Disorder & Anxiety Disorders (First-Line Agents & Safety) 12.2 Bipolar Disorder, Schizophrenia & Psychopharmacology Monitoring 12.3 Epilepsy, Seizure Types, Antiseizure Medications & Neuropathic Pain 12.4 Dementia, Parkinson Disease, Migraine, Insomnia & Restless Legs Syndrome
13 Chapter 13: Special Populations, Pain Management & Substance Use
13.1 Acute & Chronic Pain Management: Multimodal Analgesia & Opioid Stewardship 13.2 Substance Use Disorders: Opioid Agonist Therapy, Harm Reduction & Alcohol Withdrawal 13.3 Special Populations: Pharmacotherapy in Pregnancy, Lactation & Geriatrics (Deprescribing / Beers) 13.4 Palliative Care & Pediatric Pharmacotherapy
14 Chapter 14: Renal, Rheumatologic, Hematologic & Oncology Supportive Care
14.1 Chronic Kidney Disease, Acute Kidney Injury & Electrolyte Disorders 14.2 Osteoarthritis, Rheumatoid Arthritis & Gout 14.3 Anemias & Oncology Supportive Care
15 Chapter 15: Minor Ailments, Dermatology and Women's & Men's Health
15.1 Minor Ailments I: Allergic Rhinitis, Colds & Influenza, Eye and Ear Conditions 15.2 Minor Ailments II: Acne, Dermatitis, Psoriasis, Lice, Scabies & Sun Protection 15.3 Women's & Men's Health: Contraception, Emergency Contraception, Menopause, BPH, ED & Overactive Bladder
16 Chapter 16: Immunization & Health Promotion
16.1 Immunization Practice: NACI Recommendations, Administration, Cold Chain & Adverse Events 16.2 Health Promotion: Smoking Cessation, Weight Management, Screening & Social Determinants of Health
17 Chapter 17: Patient Care Process, Communication & Stewardship
17.1 The Patient Care Process: Assessment, Care Planning & Patient Interviewing 17.2 Patient Education, Device Counselling, Health Literacy & Overcoming Barriers 17.3 Interprofessional Collaboration, Pharmacy Workflow, Team Delegation & Drug Shortage Stewardship
16.2 Health Promotion: Smoking Cessation, Weight Management, Screening & Social Determinants of Health
Key Takeaways Explain This Topic AI
Combination NRT (patch plus a short-acting form) is more effective than one form, and the 4 mg gum or lozenge is used when the first cigarette is within 30 minutes of waking.
Varenicline is titrated from 0.5 mg daily to 1 mg twice daily over the first week; bupropion is contraindicated in seizure and eating disorders.
Quitting smoking removes CYP1A2 induction, so clozapine, olanzapine and theophylline levels can rise sharply; NRT does not induce CYP1A2.
Obesity pharmacotherapy is an adjunct at BMI 30 or more, or 27 or more with complications; GLP-1 agonists need slow titration and are avoided with medullary thyroid cancer or MEN2 history.
Pharmacists support screening, low-risk alcohol guidance (2 or fewer drinks a week), harm reduction such as take-home naloxone, and access barriers from social determinants of health.
Last updated: October 2026
Health Promotion: Smoking Cessation, Weight Management, Screening & Social Determinants of Health
Health promotion and disease prevention are part of the NAPRA competencies (Leadership and Stewardship, and Clinical Care). Pharmacists see patients more often than any other provider. That makes the pharmacy a natural place for smoking cessation, weight management, screening and support for people facing social barriers to health. PEBC sample items in this area test practical judgement, for example that diet and exercise prevent progression to type 2 diabetes better than any drug.
1. Smoking Cessation
Brief intervention for every tobacco user: Ask about tobacco use, Advise quitting clearly and personally, and Assist . Assisting means offering medication plus behavioural support, or referral to a quit line or program. Medication plus counselling roughly doubles to triples quit rates compared with willpower alone.
Nicotine Replacement Therapy (NRT)
Patch: 21 mg/24 h for people smoking more than 10 cigarettes a day; 14 mg for 10 or fewer. Apply to clean, hairless skin and rotate sites. Remove at bedtime if vivid dreams or insomnia occur.
Short-acting forms: gum, lozenge, inhaler, mouth spray. Use the 4 mg gum or lozenge if the first cigarette is within 30 minutes of waking , otherwise 2 mg.
Gum technique is "chew and park": chew until a peppery taste appears, then park the gum between cheek and gum, and repeat for about 30 minutes.
Avoid acidic drinks for 15 minutes before and during use.
Combination NRT (a patch for baseline needs plus a short-acting form for cravings) is more effective than any single form. Doses are often higher than the package suggests for heavy smokers. Treatment usually lasts 8 to 12 weeks or more, followed by a taper.
Safety: NRT is far safer than smoking, including in people with stable cardiovascular disease . Use caution in the first weeks after an acute coronary event. In pregnancy, behavioural support comes first; intermittent NRT forms are reasonable if needed.
Prescription and Other Options
Varenicline (now generic in Canada) is the most effective single agent:
Dosing: start 1 to 2 weeks before the quit date (or use a flexible quit date): 0.5 mg daily on days 1 to 3, 0.5 mg twice daily on days 4 to 7, then 1 mg twice daily to complete 12 weeks. Take after food with water to limit nausea.
Renal dosing: if CrCl is below 30 mL/min, the maximum is 0.5 mg twice daily.
Safety: the large EAGLES trial found no significant increase in serious neuropsychiatric events compared with placebo. Patients should still report mood changes.
Bupropion SR: 150 mg daily for 3 days, then 150 mg twice daily (at least 8 hours apart), starting 1 to 2 weeks before the quit date.
Contraindications: seizure disorders, current or past bulimia or anorexia, abrupt alcohol or benzodiazepine withdrawal, and MAO inhibitors within 14 days.
Adverse effects: insomnia and dry mouth.
Cytisine is licensed in Canada as a natural health product for smoking cessation. It is a partial nicotinic agonist like varenicline.
E-cigarettes may help some adults who smoke to quit or switch completely. They are not risk-free. Dual use offers little benefit, and youth vaping is a public health concern.
Important
Quitting changes drug levels. Tobacco smoke (polycyclic aromatic hydrocarbons, not nicotine) induces CYP1A2 . When a patient quits, levels of clozapine, olanzapine, theophylline and caffeine can rise substantially within days. Patients on clozapine need levels and dose review, because toxicity and seizures can result. NRT does not induce CYP1A2.
2. Weight Management (Obesity Canada Guideline)
Obesity is a chronic disease. Assess its root causes, complications and weight-promoting medications:
- antipsychotics such as olanzapine and clozapine;
- insulin and sulfonylureas;
- some antidepressants (mirtazapine, paroxetine);
- corticosteroids;
valproate and gabapentinoids.
Medical nutrition therapy, physical activity and psychological interventions are the foundation.
Pharmacotherapy is an adjunct for a BMI of 30 kg/m² or more, or 27 or more with weight-related complications :
Semaglutide 2.4 mg weekly or liraglutide 3 mg daily (GLP-1 receptor agonists):
Titrate slowly to limit nausea, vomiting and constipation.
Watch for gallbladder disease and pancreatitis.
Avoid with a personal or family history of medullary thyroid carcinoma or MEN2.
Pregnancy: stop before a planned pregnancy.
Surgery: tell the surgical team, because delayed gastric emptying raises the risk of aspiration during anesthesia.
Naltrexone/bupropion: contraindicated with opioid use, seizure disorders and uncontrolled hypertension.
Orlistat 120 mg with each fat-containing meal: oily stools and fecal urgency (worse with high-fat meals). Take a multivitamin with fat-soluble vitamins at bedtime , separated from orlistat. Separate levothyroxine, and monitor cyclosporine and anticonvulsant levels.
Unauthorized compounded or "research" GLP-1 products sold online are a safety risk. Counsel patients to use only authorized products.
Approach conversations about weight without stigma: ask permission, use person-first language ("a person living with obesity"), and focus on health goals rather than numbers alone.
3. Screening and Lifestyle Counselling
Pharmacy-based screening and case-finding:
- blood pressure (standardized automated measurement, section 7.1);
- diabetes risk (for example, the CANRISK questionnaire, and A1C where available);
- lipids and cardiovascular risk;
support for organized cancer screening, such as fecal immunochemical testing for colorectal cancer, usually every 2 years from ages 50 to 74 .
Physical activity: adults should aim for at least 150 minutes of moderate to vigorous activity weekly , plus muscle strengthening twice weekly (Canadian 24-Hour Movement Guidelines).
Alcohol: Canada's Guidance on Alcohol and Health (2023) describes 2 or fewer standard drinks a week as low risk , with risk rising steadily above that. No amount is risk-free.
4. Social Determinants of Health and Public Health Roles
Income, housing, food security, education, racism and colonialism shape health more than health care does. Pharmacists can:
- check drug coverage (provincial plans, NIHB, Jordan's Principle);
- choose lower-cost equivalents;
- connect patients with community resources;
use trauma-informed, culturally safe care (section 2.3).
Harm reduction: take-home naloxone kits (no prescription needed), sterile supplies, and referral to opioid agonist therapy (section 13.2).
Emergency preparedness: pharmacies keep continuity plans for disasters, pandemics and outages. These include backup power for vaccine refrigerators, access to patient records, and emergency supplies within provincial rules.